PubMed Health⌕ Search

PubMed · 11803193

Does Down's syndrome protect against multiple sclerosis?

Abstract

BACKGROUND: A higher incidence of certain autoimmune disorders has been reported in Down's syndrome (DS) but only 1 case of DS associated with multiple sclerosis (MS) has been published to date. METHODS: We performed a calculation based on population and prevalence data of each condition to estimate the expected coprevalence of both diseases. As no published data on DS prevalence are available, a rough estimate was calculated from live birth rates and published life tables. RESULTS: In a total of 116,939 assumed cases of patients with DS in Western Europe 102 patients with concordant MS would be expected at any time point according to the incidence of MS, but only 1 case was reported. CONCLUSION and HYPOTHESIS: We propose the hypothesis that despite a propensity in DS for certain autoimmune diseases there is a negative association of DS and MS. Genes located on chromosome 21 may thus confer protection against MS. Candidate genes for protective immunomodulation might include interferon receptor I and II and S100b. Substantiated by further epidemiologic data, the identification of these and other chromosome 21 gene products may provide new hints for the understanding of modulatory genes in the pathogenesis of MS. In more general terms, this negative association also may allow to study basic principles of how certain candidate genes might act on autoimmune disease expression.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Franz X Weilbach, Klaus V Toyka. 2002. Does Down's syndrome protect against multiple sclerosis?. https://doi.org/10.1159/000047947

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Fasudil induces anti-inflammatory transcriptomic changes and increased proliferation in human trisomy 21 neural progenitor cells.

Down syndrome (DS) results from trisomy for human chromosome 21 and is the most frequent genetic cause of intellectual disability. No effective treatments currently exist that improve neurodevelopment and cognition. Atypical brain development in individuals with DS is apparent before birth, which suggests that the optimal time to begin administration of therapies is prenatally. Human neural progenitor cell (NPC) cultures provide a tractable in vitro model system to examine the effects of trisomy 21 (T21) on neurodevelopment and to measure the effects of pharmacological interventions. Here, we report the results of preclinical studies evaluating 24 candidate therapies. RNA sequencing analyses found that euploid and T21 NPCs showed different transcriptomic responses to five candidate pharmacotherapies. The Rho-associated coiled-coil kinase inhibitor fasudil increased proliferation of T21 NPCs, reduced expression of inflammatory pathway genes in T21 NPCs, and reduced markers of inflammation in LPS-stimulated microglial model systems. These results demonstrate that fasudil can alter multiple T21-associated abnormalities in a beneficial manner, suggesting that fasudil warrants further study as a candidate prenatal pharmacotherapy for DS.

Down Syndrome↗